Tag: Kesimpta

Many individuals undergoing treatment for multiple sclerosis with Kesimpta experience common side effects such as headaches or injection-related discomfort, particularly following the initial doses. To manage these symptoms, a frequent question arises: **Can you take ibuprofen while on Kesimpta?**

According to the U.S. Food and Drug Administration (FDA) prescribing information, Kesimpta is contraindicated in patients with an active Hepatitis B virus (HBV) infection or a history of a life-threatening injection-related or hypersensitivity reaction to the drug. Understanding **what are the contraindications for Kesimpta** is crucial for patient safety and effective treatment planning.

While Tysabri has been a highly effective treatment for relapsing multiple sclerosis for many years, offering a 67% reduction in relapse rates compared to placebo in a 2-year clinical trial, its association with the risk of a serious brain infection (PML) has prompted many patients and neurologists to consider **what is better than Tysabri**. The answer is not a single medication, but rather a personalized evaluation of several factors to determine the best alternative for each individual.

Many people carry the John Cunningham (JC) virus, which, in those with weakened immune systems, can lead to a rare but serious brain infection called Progressive Multifocal Leukoencephalopathy (PML). For individuals with multiple sclerosis (MS) who test positive for the virus, a key question is whether they can take Kesimpta if they are JCV positive.

In clinical trials, a significant number of patients reported systemic injection-related reactions, most commonly within 24 hours of the first Kesimpta dose. This initial experience, alongside long-term side effects like increased vulnerability to infections, helps answer the crucial question: how does Kesimpta make you feel?

Over 1 million Americans are living with multiple sclerosis (MS), a chronic, unpredictable disease that affects the central nervous system. In the landscape of disease-modifying therapies (DMTs), B-cell targeting agents like Kesimpta (ofatumumab) and Ocrevus (ocrelizumab) have become cornerstones of treatment for relapsing forms of MS. Choosing which is better, Kesimpta or Ocrevus, is a complex decision that involves weighing several factors, from the method of administration to subtle differences in clinical outcomes.

A definitive medical fact is that **Kesimpta is not chemotherapy**; it is a targeted treatment that works differently within the immune system. This distinction is crucial for understanding its mechanism, applications, and potential side effects compared to traditional, aggressive chemotherapy regimens.